DentalOne Partners partners with Forward Science to offer OralID Oral Cancer Screenings
By: Forward Science
Unfortunately, oral cancer is not a rare disease; this year, approximately 53,000 individuals will be diagnosed with oral cancer in the United States alone. Due to late stage discovery, one American dies every hour from oral cancer. DentalOne Partners will now be incorporating OralID in efforts to discover oral cancers in their earliest stages. Currently, 70% of oral cancers are found in late stages (stage III, IV), resulting in a 5-year survival rate of less than 50%. Finding these abnormalities in much earlier stages can increase the 5-year survival rate up to 80-90%.
Dr. David Anderson, Chief Clinical Officer at DentalOne Partners, expressed that, "We know that oral cancer is an ugly disease and we want our patients to rest assured that our offices are providing the best care to our patients by screening them with the latest technology in OralID." He further explained that, "When we chose to partner with Forward Science, we were looking for a robust partnership to help us in educating and training our team." After the initial rollouts of DentalOne Texas markets, Dr. Anderson expressed his excitement about the new partnership, "Forward Science has set the bar high, so other companies in the dental industry should step up their game to help provide the level of support and experience that we have had in working with their team."
Forward Science's mission is that; "We believe that we can defeat cancer; cancer will not defeat us", and that is why the company is happy to partner with DentalOne Partners in efforts to change the trends of oral cancer. "We are excited about our partnership with DentalOne as our company goals are very similar: providing great patient care," shares Forward Science National Sales Director, Cassie Wilson. "The impact we can have on patients' lives is far greater than we can even imagine."
About Forward Science
Forward Science is a privately held MedTech company based in Houston, Texas. OralID, Forward Science's flagship product, is an award-winning oral cancer screening device that allows clinicians to discover abnormalities that may not be seen under traditional white light examinations. With the success of OralID, Forward Science continued to focus on moving science forward in the oral healthcare industry by launching advanced diagnostic testing products (CytID, hpvID, phID, PathID) along with treatment options (SalivaMAX, SalivaCAINE, Sitavig). In addition to developing proprietary, state-of-the-
To learn more about any of Forward Science's products, please visit https://www.ForwardScience.com or call 855-696-7254.
About DentalOne Partners
When practices are supported in genuine partnerships, exciting new possibilities arise: Overhead is reduced. Processes are streamlined. Purchasing power and efficiencies are increased. And doctors are free to devote more time to patient care. In 1981, we set out to help doctors enhance their capabilities, grow their practices, and operate more efficiently by leveraging the power of partnership. Our commitment to becoming the largest Dental Healthcare Provider in the U.S. will enable us to create even greater opportunities in the years ahead — and better support the doctors and patients we serve.